Literature DB >> 11261454

Effectiveness of inhaled corticosteroids in controlling acute asthma exacerbations in children at home.

B Volovitz1, M Nussinovitch, Y Finkelstein, L Harel, I Varsano.   

Abstract

Many clinicians advise their patients to increase the dose of inhaled corticosteroids during acute asthma exacerbations, without strong clinical evidence supporting this treatment. This study investigates the effectiveness of inhaled corticosteroids in controlling acute asthma exacerbations in children at home. The study population consisted of children with mild intermittent, mild and moderate persistent asthma aged 1 to 14 years who were treated in our outpatient clinic with inhaled budesonide for 1 year. After participating in an asthma education session, the parents were instructed to initiate treatment with inhaled budesonide at the first signs of asthma exacerbation, starting with 200 to 400 microg budesonide, in combination with beta-2 agonists 4 times a day and followed by a decrease in the dose in 4 to 8 days. Asthma status and peak expiratory flow rates were measured in the 3 monthly follow-up visits. Only children who complied with the treatment regimen and came for follow-up visits regularly were included in the final analysis. One hundred fifty children used our treatment protocol with inhaled budesonide to control their asthma attacks. Clinical improvement of asthma symptoms was achieved after a mean of 1.8 +/- 0.7 days from the beginning of treatment. The parents were able to control 94% of the 1,061 episodes of asthma exacerbation occurring during a cumulative follow-up period of 239 years. In the 3-month period before enrollment, 101 children (67%) had used oral corticosteroids to control their asthma attacks and 50 (33%) were hospitalized. During the entire follow-up period, only 11 children (7%) used oral corticosteroids, and none of the children were hospitalized. The present study demonstrates that children with asthma can control their exacerbations at home using inhaled corticosteroids (budesonide). Treatment, starting with relatively high doses followed by a rapid reduction in dose over 4-8 days, resulted in a decrease in the use of oral steroids and in hospitalization. To achieve good results, patient compliance is essential.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11261454     DOI: 10.1177/000992280104000203

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  10 in total

1.  As Needed Use of Inhaled Corticosteroids for Management of Mild Persistent Asthma in Children.

Authors:  Hengameh H Raissy; Kathryn Blake
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2011-12       Impact factor: 1.349

Review 2.  Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003.

Authors:  Allan Becker; Catherine Lemière; Denis Bérubé; Louis-Philippe Boulet; Francine M Ducharme; Mark FitzGerald; Thomas Kovesi
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

3.  Pharmacotherapy--treatment of intermittent asthma with ICSs.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

4.  Signs and symptoms that precede wheezing in children with a pattern of moderate-to-severe intermittent wheezing.

Authors:  Katherine Rivera-Spoljaric; Vernon M Chinchilli; Lindsay J Camera; Robert S Zeiger; Ian M Paul; Brenda R Phillips; Lynn M Taussig; Robert C Strunk; Leonard B Bacharier
Journal:  J Pediatr       Date:  2009-03-25       Impact factor: 4.406

Review 5.  Management of children with severe asthma exacerbation in the emergency department.

Authors:  Benjamin Volovitz; Moshe Nussinovitch
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Empowering the child and caregiver: yellow zone Asthma Action Plan.

Authors:  Chitra Dinakar; Jay M Portnoy
Journal:  Curr Allergy Asthma Rep       Date:  2014-11       Impact factor: 4.806

Review 7.  Inhaled steroids for acute asthma following emergency department discharge.

Authors:  Marcia L Edmonds; Stephen J Milan; Barry E Brenner; Carlos A Camargo; Brian H Rowe
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

8.  Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations.

Authors:  Daniel J Jackson; Leonard B Bacharier; David T Mauger; Susan Boehmer; Avraham Beigelman; James F Chmiel; Anne M Fitzpatrick; Jonathan M Gaffin; Wayne J Morgan; Stephen P Peters; Wanda Phipatanakul; William J Sheehan; Michael D Cabana; Fernando Holguin; Fernando D Martinez; Jacqueline A Pongracic; Sachin N Baxi; Mindy Benson; Kathryn Blake; Ronina Covar; Deborah A Gentile; Elliot Israel; Jerry A Krishnan; Harsha V Kumar; Jason E Lang; Stephen C Lazarus; John J Lima; Dayna Long; Ngoc Ly; Jyothi Marbin; James N Moy; Ross E Myers; J Tod Olin; Hengameh H Raissy; Rachel G Robison; Kristie Ross; Christine A Sorkness; Robert F Lemanske
Journal:  N Engl J Med       Date:  2018-03-03       Impact factor: 91.245

9.  2003 canadian asthma consensus guidelines executive summary.

Authors:  Allan Becker; Catherine Lemière; Denis Bérubé; Louis-Philippe Boulet; Francine Ducharme; Mark Fitzgerald; Thomas Kovesi
Journal:  Allergy Asthma Clin Immunol       Date:  2006-03-15       Impact factor: 3.406

Review 10.  6. Asthma.

Authors:  Robert F Lemanske; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.